The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 478 participants.

Also called NCT02536196

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 478 participants (enrolled count) (from the registry)
Sponsor
Keystone Heart (from the registry)
Registry
  • NCT NCT02536196
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Germany, Italy, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02536196. Randomized; single masking; primary purpose prevention. Start 2016-06 (actual); primary completion 2019-05 (actual). Results posted on 2021-02-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation
Condition
Symptomatic Aortic Stenosis
Intervention (Device)
Embolic Protection Device
Intervention (Procedure)
Transcatheter aortic valve implantation (TAVI)
Lead sponsor
Keystone Heart (class: industry)

Record details

Record id
cardio:ct-nct02536196
Content hash
de66af9d565520b0fb32b415df9a24c942e0c4b6b4f96b97b2689c02caad8166